Armata Pharmaceuticals climbed 12% this week to $12.92, capping a 57% month-long run. Short interest rose 17% over thirty days to 337k shares. Analysts hold a $17.50 target. CEO and CFO sold shares in mid-March near $10.54.
ARMP closed at $12.92 on April 24, down 4.5% on the day. The stock gained 12.3% for the week and 57.4% for the month. The sharp monthly rally reversed prior weakness and pushed shares well above early-year lows.
Short interest sits at 336,549 shares as of April 23, representing 0.93% of the float. Shares shorted climbed 16.6% over the past month from 288,838 shares on March 13. The one-week change was 3.3% higher. Daily movements have been choppy — short interest peaked at 346,061 shares on April 22 before falling 2.7% the next day.
Cost to borrow averaged 5.64% as of April 22, up 10.1% over the prior week. The metric has oscillated in a 4.3%–6.1% range over the past month. CTB reached 6.11% on March 19 before easing. Current levels remain 7.7% below the month-ago mark of 6.11%.
Utilisation stood at 6.1% on April 23. This is well below the 52-week high of 44.82%. Utilisation more than doubled from 2.3% in late March to 7.6% on April 22, then pulled back. The recent climb mirrors the uptick in short interest.
The put/call ratio hit 0.8548 on April 24. The 20-day mean is 0.6424 with a standard deviation of 0.13. The current reading sits 1.65 standard deviations above the mean, signaling elevated hedging demand. The 52-week range spans 0.00 to 3.59. PCR spiked to 3.59 in mid-March before settling back to recent levels.
Two firms cover the stock with a $17.50 mean price target. HC Wainwright raised its target from $9 to $15 on February 23, maintaining a Buy rating. Jones Trading initiated coverage with a Buy and $15 target on January 5. Both firms are constructive on the biotech's pipeline. The $17.50 target implies 35% upside from current levels.
Armata carries negative P/E and EV/EBITDA multiples tied to pre-profitability operations. The P/E of -2.97 worsened by 0.50 points over thirty days. EV/EBITDA of -3.29 improved modestly by 0.01 over the same span. Enterprise value stood at $664 million as of year-end 2025.
Factor ranks place the stock at the 99th percentile for earnings surprise and 79th for sector score. Dividend score sits at the 32nd percentile. Short score ranks at the 41st percentile, days to cover at 51st, utilisation at 63rd.
Innoviva holds 25.1 million shares, representing 68.5% of the company. The position was unchanged as of its January 23 filing. Vanguard added 60,611 shares in Q1 to reach 357,649, or 0.98%. BlackRock lifted its stake by 46,098 shares to 72,764. Renaissance Technologies acquired 27,200 shares in Q4, bringing its holding to 68,496. Goldman Sachs initiated a 45,163-share position last quarter. 683 Capital Management disclosed a new 139,860-share stake at year-end.
CEO Deborah Birx sold 4,919 shares at $10.54 on March 13 for $51,846. Chief Level Officer Pierre Kyme sold 1,030 shares at the same price for $10,856. The 90-day net across all insiders shows 5,949 shares sold for $62,702. Birx previously sold 13,637 shares in July 2025 at $2.27. Innoviva built its majority stake through multiple 2021–2022 purchases at prices ranging from $3.25 to $5.00 per share.
The company is scheduled to report earnings on May 7. Prior events occurred on March 25 and April 1. No historical price reaction data is available for recent prints. Investors will look for pipeline updates and cash burn metrics given the pre-revenue stage.
See the live data behind this article on ORTEX.
Open ARMP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
